<?xml version="1.0" encoding="UTF-8"?>
<ref id="B11-biomedicines-08-00060">
 <label>11.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>McArthur</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>Chapman</surname>
    <given-names>P.B.</given-names>
   </name>
   <name>
    <surname>Robert</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Larkin</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Haanen</surname>
    <given-names>J.B.</given-names>
   </name>
   <name>
    <surname>Dummer</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Ribas</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Hogg</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Hamid</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Ascierto</surname>
    <given-names>P.A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study</article-title>
  <source>Lancet Oncol.</source>
  <year>2014</year>
  <volume>15</volume>
  <fpage>323</fpage>
  <lpage>332</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70012-9</pub-id>
  <pub-id pub-id-type="pmid">24508103</pub-id>
 </element-citation>
</ref>
